KDR and neoplasm: By inhibiting VEGFR-2, Apatinib can effectively inhibit tumor angiogenesis and improve the tumor microenvironment, thereby reducing the supply of nutrients and oxygen to tumor cells and limiting tumor growth and metastasis.